Greenland Mines (NASDAQ: GRML) announced that IP Australia has granted Australian Patent No. 2023252508, covering gene therapy technology exclusively licensed by the company’s Biotech Division for the treatment of neuromuscular diseases through expression of the human Klotho protein. The patent strengthens the intellectual property supporting Greenland Mines’ Klotho-based therapeutic platform and includes claims covering gene therapy constructs, neuronal and induced pluripotent stem cells, and viral and non-viral delivery systems. The company said the patent further supports development of its KLTO-202 program targeting amyotrophic lateral sclerosis (“ALS”) and other neuromuscular disorders.
The granted patent provides broad protection for the company's approach to delivering the Klotho gene, which has shown potential in preclinical studies for neuroprotection and extending lifespan. By securing this patent in Australia, Greenland Mines adds to its growing portfolio of intellectual property rights aimed at advancing gene therapies for debilitating diseases. The patent covers key aspects of the technology, including methods for expressing Klotho in neuronal cells and stem cells, as well as various delivery mechanisms that could be used in therapeutic applications.
This development is significant because it enhances the company's ability to protect its innovations and potentially attract partners or investors interested in the rapidly evolving field of gene therapy. The KLTO-202 program, which targets ALS, represents a promising application of the Klotho gene therapy platform. ALS is a progressive neurodegenerative disease with limited treatment options, and new therapies are urgently needed. The Australian patent provides a competitive edge in that market and bolsters the company's overall strategy of building a multi-asset platform with exposure to rare earth materials and biotech.
The patent also reflects Greenland Mines' commitment to its Biotech Division, which is part of a broader corporate strategy centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals, and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure. The company's mining division focuses on exploration and development of the Skaergaard Project in southeast Greenland and, subject to closing of a previously announced transaction, the Sarfartoq neodymium-praseodymium (Nd-Pr) rare earths project in southwest Greenland.
For more details on the patent announcement, the full press release is available at https://nnw.fm/PVbbH. The latest news and updates relating to GRML are available in the company’s newsroom at https://ibn.fm/GRML.
Forward-looking statements in this article involve risks and uncertainties that may cause actual results to differ materially. These include factors set forth under "Risk Factors" in the company's SEC filings. Undue reliance should not be placed on forward-looking statements, and the company undertakes no duty to update this information unless required by law.
